<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040157</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-006</org_study_id>
    <nct_id>NCT00040157</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.</brief_title>
  <official_title>A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection
      who have modestly detectable viral load while on stable triple combination antiretroviral
      therapy including 3TC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety concerns
  </why_stopped>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH126-443 (Beta-L-Fd4C)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years of age

          -  Receiving a stable triple combination antiretroviral regimen including 3TC, one other
             NRTI and either an NNRTI or a protease inhibitor for at least 4 months (16 weeks)

          -  Demonstration of initial viral suppression and subsequent rebound to be defined as an
             initial virological drop of at least 0.5 Logs on a 3TC-containing regimen

          -  Plasma HIV RNA level &gt; 1000 and &lt; 30,000 copies/mL on two occasions

          -  Genotypically documented M184V variant of HIV RT

          -  Clinically stable HIV status with no AIDS-defining events

          -  CD4 &gt; 200 cells/mm3

          -  Basic hematologic and chemistry parameters within acceptable limits (defined in
             protocol)

          -  All women of child bearing potential must have a negative serum or urine pregnancy
             test (minimum sensitivity of 25 IU/L of b-HCG) within 72 hours prior to the start of
             study medication

          -  No active opportunistic infection requiring treatment

          -  Subject must be able to provide written informed consent

          -  Baseline laboratory values measured within 28 days of initiating study drug as
             follows:

          -  HGB≥9.0g/dl or HCT≥27% (in the absence of blood transfusions or erythropoietin
             treatment in the preceding two weeks

          -  Absolute neutrophil count≥1000 cells/mm(^3) (in the absence of on-going G-CSF therapy

          -  Platelet count ≥75,000/mm(^3)

          -  AST &lt;7.0 times the upper limit of normal

          -  ALT ,7.0 times the upper limit of normal

          -  Serum creatinine &lt;1.1 times the upper limit of normal

        Exclusion Criteria

          -  Evidence of active HBV infection as demonstrated by HBsAg positivity

          -  Hepatitis C co-infection

          -  Concurrent systemic antiviral treatment

          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic
             potential within 3 months of study start or the expected need for such therapy at
             study start.

          -  Alcohol abuse

          -  Pregnancy or breast-feeding

          -  Inability to tolerate oral medication

          -  AST &gt; 7.0 times the upper limit of normal

          -  ALT &gt; 7.0 times the upper limit of normal

          -  Any clinical condition or prior therapy that, in the Investigators opinion, would make
             the subject unsuitable for the study or unable to comply with the dosing requirements.

          -  Use of any other drug or substance with anti-HBV activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Body Positive, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L.a.</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Horizon Medical Group, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Care Center One, Inc.</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Infectious Disease, Dept. of Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Road Medical Specialists</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.achillion.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2002</study_first_submitted>
  <study_first_submitted_qc>June 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2002</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <keyword>treatment experienced,</keyword>
  <keyword>Stable triple anti-retroviral combination therapy in HIV-infected,</keyword>
  <keyword>Achillion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

